Injectable Formulations
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 17/006,115, filed Aug 28, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,406,619 | Injectable Formulations In force · High confidence | Cybin UK Ltd. | In force | High confidence | ||
| US 12,343,327 | Injectable Formulations In force · High confidence | Cybin UK Ltd. | In force | High confidence | ||
| Application 17/006,115 | Injectable Formulation Abandoned Abandoned Aug 1, 2022 | Cybin UK Ltd. | Abandoned | Abandoned Aug 1, 2022 | ||
| Application 19/202,059 | Injectable Formulations Pending Not granted | Cybin UK Ltd. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Cybin UK Ltd..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.